Back to the main directory
EarningsReview / Equity
- Ultimovacs - On track for upcoming UV1 catalysts by Edison Investment Research
- ACS - 3Q22 Results: In-line at operating and CF levels, on track for shareholder remuneration; Buy by JB Capital Markets
- Sonae - 3Q22 Conference Call: Food retail gaining share, increased stake in NOS; we reiterate Buy by JB Capital Markets
- Novabase - 3Q22 results affected by delays in revenue recognition for Next-Gen, should recover by 4Q22; reiterating Buy by JB Capital Markets
- Vista Alegre - 3Q22 Results: FCF generation is positive despite expected margin pressures; Neutral by JB Capital Markets
- Itaú BBA on Empresas Copec: Slowing Fuel Volumes in Chile in 3Q22, Pulp Still Positive by Itau
- SalMar (Buy, TP: NOK400.00) - Dust starting to settle by DnB Markets
- ALK-Abello (Buy, TP: DKK140.00) - Focus shift to 2023 by DnB Markets
- Icelandic Salmon (Buy, TP: NOK180.00) - A bump in the road by DnB Markets
- Safe Bulkers (Buy, TP: USD6.60) - Route to 2023e recovery by DnB Markets
- AF Gruppen (Sell, TP: NOK105.00) - Q3 miss by DnB Markets
- GN Group (Buy, TP: DKK280.00) - Focus on GN Hearing guidance by DnB Markets
- Weekly news, topics & discussion by DnB Markets
- China Oil & Gas by HSBC
- Micro Star (2377 TT) by HSBC
- Itaú BBA on Kora Saúde: 3Q22 – In-Line Volume Trends; Margins Under Pressure by Itau
- Itaú BBA on Cemig: EBITDA Miss Due to Weaker Genco by Itau
- Dis-Chem Pharmacies (DCP SJ) by HSBC
- Moving on to greener pastures by BNP Paribas Exane
- Seeing the wood for the trees by BNP Paribas Exane
- Model update amidst the newsflow by BNP Paribas Exane
- FCF takes another hit but reasons to be optimistic by BNP Paribas Exane
- So what is the right multiple? by BNP Paribas Exane
- 2022 guidance seems too prudent, expect a rosy 2023 by BNP Paribas Exane
- It''s all about spreads and having a plan by BNP Paribas Exane